CD19 and neoplasm: Importantly, in the in vivo model used in this study, which aimed to demonstrate the capacity of CD19/NKG2DL tandem CAR T-cells to control CD19- tumor cells, NKG2DL single and tandem CAR T-cells demonstrated comparable anti-tumor efficacy.